Faculty of Advanced Medical Sciences, Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Institute for Fundamental Sciences (RIFS), University of Tabriz, Tabriz, Iran.
J Cell Physiol. 2018 Apr;233(4):2982-2992. doi: 10.1002/jcp.26051. Epub 2017 Aug 23.
As a young science, nanotechnology promptly integrated into the current oncology practice. Accordingly, various nanostructure particles were developed to reduce drug toxicity and allow the targeted delivery of various diagnostic and therapeutic compounds to the cancer cells. New sophisticated nanosystems constantly emerge to improve the performance of current anticancer modalities. Targeting tumor vasculature is an attractive strategy to fight cancer. Though the idea was swiftly furthered from basic science to the clinic, targeting tumor vasculature had a limited potential in patients, where tumors relapse due to the development of multiple drug resistance and metastasis. The aim of this review is to discuss the advantages of nanosystem incorporation with various vascular targeting agents, including (i) endogen anti-angiogenic agents; (ii) inhibitors of angiogenesis-related growth factors; (iii) inhibitors of tyrosine kinase receptors; (iv) inhibitors of angiogenesis-related signaling pathways; (v) inhibitors of tumor endothelial cell-associated markers; and (vi) tumor vascular disrupting agents. We also review the efficacy of nanostructures as natural vascular targeting agents. The efficacy of each approach in cancer therapy is further discussed.
纳米技术作为一门年轻的科学，迅速融入了当前的肿瘤学实践。相应地，开发了各种纳米结构颗粒来降低药物毒性，并允许将各种诊断和治疗化合物靶向递送到癌细胞。新的复杂纳米系统不断涌现，以提高当前抗癌模式的性能。靶向肿瘤血管是一种有吸引力的抗癌策略。尽管这一想法从基础科学迅速推进到临床，但由于多种耐药性和转移的发展，肿瘤复发，靶向肿瘤血管在患者中的潜力有限。本综述的目的是讨论将纳米系统与各种血管靶向剂结合的优势，包括 (i) 内源性抗血管生成剂；(ii) 血管生成相关生长因子抑制剂；(iii) 酪氨酸激酶受体抑制剂；(iv) 血管生成相关信号通路抑制剂；(v) 肿瘤内皮细胞相关标志物抑制剂；和 (vi) 肿瘤血管破坏剂。我们还回顾了纳米结构作为天然血管靶向剂的功效。进一步讨论了每种方法在癌症治疗中的疗效。
